Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

RADAR-AD · Remote Assessment of Disease and Relapse – Alzheimer’s Disease

H2020Status: CLOSED1 January 201930 June 2023EU funding €4,999,757Call H2020-JTI-IMI2-2017-12-two-stage

There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful combination of smartphone, wearable and/or home sensor based parameters. The system developed will be suitable for future longitudinal studies, including trials. The objectives are to 1) Identify the most relevant functional domains and the most promising remote measurement tools (RMTs) for these domains based on reviewing the literature and piloting of RMTs in small studies; 2) Optimise the RADAR-CNS platform for use in AD studies; 3) Test the platform and selected RMTs in a real world environment clinical study with 240 participants across the AD spectrum ranging from the preclinical AD to the dementia stage; 4) Perform statistical modelling to estimate longitudinal predictions; 5) Discuss results with regulatory agencies in order to obtain guidance about how to develop a path for formal qualification as outcome measurements in future therapeutic interventions. Considering the limited budget and project duration, we will rely upon already available technology platforms and on available longitudinal datasets where possible. The consortium includes experts in clinical dementia studies, computer science, bioinformatics, regulatory policies, ethics, and patient and public involvement (PPI). Additional strengths of the consortium are the deep and broad interface with RADAR-CNS and related IMI projects, and the access to large amount of patient-level data from key European cohort studies for modelling purposes.

Consortium · 17 organisations

coordinator

KING'S COLLEGE LONDON

UK · €882,041

participant

SOFTWARE AG

DE

participant

ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS

EL · €349,377

participant

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

CH

participant

STICHTING LYGATURE

NL · €688,920

participant

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €247,250

participant

NOVARTIS PHARMA AG

CH

participant

THE HYVE BV

NL · €467,203

participant

TAKEDA DEVELOPMENT CENTRE EUROPE LTD

UK

participant

STICHTING AMSTERDAM UMC

NL · €1,273,127

participant

KAROLINSKA INSTITUTET

SE · €124,096

participant

AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN

NL · €50,000

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €717,243

participant

ELI LILLY AND COMPANY LTD

UK

participant

ALZHEIMER EUROPE

LU · €200,500

participant

ALTOIDA AG

CH

participant

JANSSEN PHARMACEUTICA NV

BE

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.